her2-low breast cancer: the esmo expert consensus statements
Published 1 year ago • 934 plays • Length 2:02Download video MP4
Download video MP3
Similar videos
-
6:39
expert report on advances in the management of her2-negative and her2-low advanced breast cancer
-
7:30
#esmo21 expert video report on her2-positive metastatic breast cancer
-
4:50
expert report on tackling resistance to cdk4/6 inhibitors in er /her2-metastatic breast cancer
-
8:31
#esmo21 expert video report on her2-positive early breast cancer
-
5:32
esmo 2020 expert video report on cdk4 6i in the adjuvant treatment of breast cancer
-
1:59
breast cancer: essentials for clinicians on breast cancer
-
5:45
#esmo21 expert video report on targeting in her2-positive metastatic breast and lung cancers
-
6:48
how to use endocrine therapy in premenopausal women with er early breast cancer
-
21:47
esmo daily reporter talk: the role of cdk4/6 inhibitors in the early stage of #breastcancer.
-
4:46
her2 mutations in cancer
-
7:15
asco 2023 expert report in hr positive, her2 negative breast cancer by catherine harper-wynne
-
6:28
esmo expert report on antibody drug conjugates in the management of urothelial cancer @asco gu 2022
-
1:10
the evolution of her2-low-positive breast cancer as a clinical subtype
-
1:31
esmo oncologypro - intro by prof. a. matikas
-
1:35
advances in novel adcs for her2-expressing breast cancer
-
1:16
her2-low expression in breast cancer
-
1:09
the exciting new field of her2-low breast cancer
-
7:36
esmo 2020 expert video report on atezolizumab in upfront treatment of tnbc